Sandoz Africa: Jacques van Wyk

Jacques van Wyk has been the Chief Financial Officer of Sandoz Africa since March 2016.

Jacques van Wyk has a Bachelor of Commerce Degree in Accounting and Business Economics from the University of the Free State and a Management Accountant qualification from the Chartered Institute of Management Accountants. After serving as Assistant Manager at N&M Agencies, he did temporary assignments for various companies before working for Ranbaxy for almost seven years. He then joined Sandoz as Chief Financial Officer of South and East Africa and was later promoted to Chief Financial Officer of Sandoz Africa. 

Work
2016 – Present    Chief Financial Officer, Sandoz Africa
2009 – 2016         Chief Financial Officer, Sandoz South and East Africa
2007 – 2009         Finance Manager: Be-Tabs Pharmaceuticals, Ranbaxy
2006 – 2007         Management Accountant, Ranbaxy
2003 – 2005         Finance Executive, Ranbaxy Africa
2002 – 2003         Financial Management Accountant, Ranbaxy
2000 – 2001         Accounts Assistant, S3 Computer Recruitment 
2000 – 2000         Accounts Payable Clerk, Denton Wilde Sapte
2000 – 2000         Accounts Assistant, Mark Allen Group
2000 – 2000         Accounts Payable Clerk, NCH Action for Children
1999 – 1999         Accounts Assistant, Trobridges
1999 – 1999         Accounts Assistant, Tecalemit Garage Equipment
1995 – 1999         Assistant Manager, N&M Agencies

Education
2005 – 2006         ACMA, CIMA
1993 – 1996         B.Com, Accounting and Business Economics,                                                                  University of the Free State

About Sandoz: Sandoz is a global leader in generic and biosimilar, generic antibiotics, dermatology and transplantation medicines, as well as generic cardiovascular, central nervous system, pain and ophthalmology to oncology, respiratory and hormonal therapeutics areas. At Sandoz, they discover new ways to improve and extend people’s lives. They pioneer novel approaches to help people around the world access high-quality medicine. In 2015, their products reached an estimated 520 million patients.